Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Follow-Up Questions
Phathom Pharmaceuticals Inc 的 CEO 是谁?
Mr. Steven Basta 是 Phathom Pharmaceuticals Inc 的 President,自 2025 加入公司。
PHAT 股票的价格表现如何?
PHAT 的当前价格为 $13.78,在上个交易日 increased 了 6.36%。
Phathom Pharmaceuticals Inc 的主要业务主题或行业是什么?
Phathom Pharmaceuticals Inc 属于 Pharmaceuticals 行业,该板块是 Health Care